Haemonetics share price logo

Haemonetics

NYSE: HAE

Mid Cap

$108.40

+0.80

(+0.74%)

as on

Haemonetics Stock Performance

as on September 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $107.60
    $110.45
    downward going graph

    0.74%

    Downside

    1.89%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $47.32
    $109.83
    downward going graph

    56.35%

    Downside

    1.32%

    Upside

    downward going graph

Haemonetics share price movements today

Previous Close
$107.60
Open
$108.11
Volume
476.8K
Market Cap
$4.9B
Day's Low - High
$107.60 - $110.45
52 Week Low - High
$47.32 - $109.83

Haemonetics Historical Returns

1 Month Return
-0.75 %
3 Month Return
+ 45.07 %
1 Year Return
+ 112.65 %
3 Year Return
+ 17.8 %
5 Year Return
+ 53.23 %

Haemonetics Stock Fundamentals & Key Indicators

Check Haemonetics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.9B

EPS (TTM)

2.06

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

52.23

Industry PE ratio

18.93

PEG Ratio

-1.397126845054858

EBITDA

261.2M

Revenue (TTM)

1.4B

Profit Margin

57.38%

Return On Equity TTM

11.35%

Haemonetics Stock Valuation

Track how Haemonetics P/E has moved over time to understand its valuation trends.

Haemonetics in the last 5 years

  • Overview

  • Trends

Lowest (19.09x)

March 31, 2025

Industry (18.93x)

March 31, 2026

Today (26.36x)

March 31, 2026

Highest (74.40x)

March 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 26.36x

Haemonetics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Haemonetics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$4.9B53.23%52.2357.38%0.00%
BUY$50.9B-26.1%50.7277.98%0.00%
BUY$119.9B-28.47%22.6866.69%3.08%
BUY$176.6B-19.37%32.8156.80%2.42%
BUY$108.0B2.6%28.7965.17%1.22%

Stock Returns calculator for Haemonetics Stock including INR - Dollar returns

The Haemonetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Haemonetics investment value today

Current value as on today

₹2,33,148

Returns

₹1,33,148

(+133.15%)

Returns from Haemonetics Stock

₹1,14,229 (+114.23%)

Dollar Impact

₹18,918 (+18.92%)

Analyst Recommendation on Haemonetics Stock

Based on 9 analysts

BUY

77.78%

Buy

22.22%

Hold

0.00%

Sell

Based on 9 analysts, 77.77777777777779% of analysts recommend a 'BUY' rating for Haemonetics. Average target price of $108.4

Haemonetics Share Price Target

Get share price movements and forecasts by analysts on Haemonetics.

Target Price

$108.4

Current Price

$108.4

Analyzed by

9 Analysts

Target

$108.40

Haemonetics target price $108.4, a slight upside of 0% compared to current price of $108.4. According to 9 analysts rating.

Indian Investors' Interest in Haemonetics Stock

Search interest for Haemonetics Stock has increased by 242% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:242% versus previous 30 day period

Haemonetics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
343
336
345
348
330
321
327
338
346
339
Gross Profit
188
179
191
199
181
191
183
191
198
202
Operating Income
29
39
51
59
51
53
67
69
51
57
EBITDA
68
80
88
95
98
93
86
95
4
74
Interest Expense
6
-
6
9
-
4
7
8
5
9
Depreciation
19
29
29
29
28
28
28
27
27
27
Income Before Tax
23
46
44
49
70
45
51
59
-28
47
Income Tax Expense
3
8
10
12
12
11
12
15
-8
14
Net Income
20
38
33
37
57
34
38
44
-20
33
Net Profit Margin
55.04%
53.33%
55.34%
57.36%
55.03%
59.70%
56.04%
56.47%
57.23%
59.76%

Haemonetics Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
886
903
967
988
870
993
1,168
1,309
1,360
1,334
Gross Profit
378
411
417
487
428
530
622
711
778
743
Operating Income
-19
56
83
103
89
80
156
164
221
241
EBITDA
123
153
192
257
184
191
252
295
355
312
Interest Expense
8
4
9
16
16
17
14
13
9
28
Depreciation
84
89
109
92
84
86
84
88
108
155
Income Before Tax
-27
59
73
87
72
63
141
151
212
128
Income Tax Expense
-1
14
18
10
-6
20
26
34
44
30
Net Income
-26
45
55
76
79
43
115
117
167
97
Net Profit Margin
42.71%
45.57%
43.15%
49.35%
49.22%
53.44%
53.30%
54.38%
57.21%
55.74%

Haemonetics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
20
38
33
37
57
34
38
44
-20
33
Operating Cash Flow
64
-27
48
43
116
17
111
93
70
52
Investing Cash Flow
-13
-139
-23
-17
18
-33
-30
-29
-86
-22
Financing Cash Flow
-63
333
-74
1
-151
-2
-76
2
-101
-51
Change in Cash
-15
165
-45
21
-14
-13
3
66
-117
-22

Haemonetics Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
-26
45
55
76
79
43
115
117
167
97
Operating Cash Flow
159
220
159
158
108
172
273
181
181
293
Investing Cash Flow
-73
-63
-116
-57
-425
-86
-143
-322
-161
-179
Financing Cash Flow
-60
-120
-50
-131
367
-15
-100
38
108
-178
Change in Cash
24
40
-10
-32
54
67
24
-105
127
-61

Mutual Funds that own Haemonetics Stock

Check out the Mutual Funds with significant holdings in Haemonetics.

Funds
Holdings
Shares Held
NEUBERGER BERMAN EQUITY FUNDS
8.24931%
3753193
VANGUARD INDEX FUNDS
8.175716%
3719710
AQR Funds
2.138573%
972988
Fidelity Concord Street Trust
1.901771%
865250
ALLSPRING FUNDS TRUST
1.407126%
640201

Global Institutional Holdings in Haemonetics

Funds
Holdings
iShares
11.89%
Vanguard
9.37%
John Rogers
4.53%
SPDR
2.36%
Ken Fisher
1.46%

Haemonetics News & Key Events

  • img

    Today's Timeline - 17 September

    Thu, 02:12 PM

    -

    Haemonetics faces flat sales and needs product improvements, indicating challenges in growth strategy.

    Thu, 02:50 PM

    -

    Citi upgrades Haemonetics to Buy with a $123 price target; other firms also raise price targets.

Insights on Haemonetics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, HAE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -20.14M → 33.00M (in $), with an average increase of 161.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, HAE stock has moved up by 5.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Edwards Lifesciences Corp has given 20.9% return, outperforming this stock by 2.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 346.35M → 339.38M (in $), with an average decrease of 2.0% per quarter

About Haemonetics

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
OrganisationHaemonetics
Headquarters125 Summer Street, Boston, MA, 02110, US
IndustryMedical - Devices
CEOChristopher A. Simon
E-voting on sharesClick here to vote

Key Management of Haemonetics

Name

Title

Mr. James C. D'Arecca CPA

CFO, Executive VP & Financial Officer

Mr. Frank W. Chan Ph.D.

Executive VP & COO

Ms. Michelle L. Basil Esq., J.D.

Executive VP, General Counsel & Secretary

Mr. Roy Galvin

Executive VP & Chief Commercial Officer

Ms. Olga Guyette

VP of IR & Treasury

Mr. Josh Gitelson

Senior Director of Global Communications

Mr. Christopher A. Simon

CEO, President & Director

Ms. Farris Maryanne E. Maunsell

VP, Chief Accounting Officer & Principal Accounting Officer

Mr. Rajeev Varma

Senior Vice President of Strategy & Corporate Development

Ms. Laurie A. Miller

Senior VP & Chief Human Resources Officer

FAQs

What is Haemonetics share price today?

Haemonetics share price today is $108.40 as on at the close of the market. Haemonetics share today touched a day high of $110.45 and a low of $107.60.

What is the 52 week high and 52 week low for Haemonetics share?

Haemonetics share touched a 52 week high of $109.83 on and a 52 week low of $47.32 on . Haemonetics stock price today i.e. is closed at $108.40,which is 1.30% down from its 52 week high and 129.10% up from its 52 week low.

What is Haemonetics's market capitalisation today?

Haemonetics market capitalisation is $0.00T as on .

How to invest in Haemonetics Stock (HAE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Haemonetics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Haemonetics Shares that will get you 0.0138 shares as per Haemonetics share price of $108.40 per share as on September 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Haemonetics Stock (HAE) from India?

Indian investors can start investing in Haemonetics (HAE) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Haemonetics stock (as per the Rupee-Dollar exchange rate as on ). Based on Haemonetics share’s latest price of $108.40 as on September 19, 2026 at 8:46 am IST, you will get 0.0923 shares of Haemonetics. Learn more about fractional shares .

What are the returns that Haemonetics has given to Indian investors in the last 5 years?

Haemonetics stock has given 53.23% share price returns and 30.29% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?